LaNova Medicines Successfully Completed Series A Financing

In November 2020, LaNova Medicines completed the series A financing with Qiming Venture Partners as the leading investor and China Renaissance as the financial adviser. Investors also include global or domestic well-known PE / VCs, such as TF Capital, Yingke PE, Hony Capital, Biotrack Capital, YF Capital, etc.

About Leading Investor Qiming Venture Partners:

Qiming Venture Partners is a top-tier VC firm with outstanding reputation. Qiming has been widely recognized by investors from around the world and has become an ideal VC firm for entrepreneurs. With its exceptional investment performances, Qiming has won multiple world-renowned venture capital awards. Website: https://www.qimingvc.com/